vaccination News
-
Corona vaccination at Heimbach Düren
When it was announced at the beginning of May that company doctors would be allowed to administer the Corona vaccination, our HR department immediately rolled up its sleeves and started preparations. 157 employees took advantage of the vaccination offer. The first round of vaccinations took place in June, the second in July. We hope to be able to return to a "normal" daily routine ...
-
Company doctor vaccinates at HSM
Since 07.06.2021, vaccination prioritisation in Germany has been lifted and anyone interested can apply for an appointment to be vaccinated against Covid 19, regardless of age or previous illnesses. But it is not as easy as it sounds – appointments in vaccination centres are rarely available and there is also great demand among general practitioners. For this reason, HSM GmbH + Co. KG ...
-
Dosing completed
All volunteers have now received three doses of 2AP01 (AAVLP-HPV), our very broad spectrum HPV vaccine formulated without adjuvant. The vaccine is well tolerated and no serious adverse events (SAEs)have been observed to ...
-
NovaDigm Therapeutics Strengthens Candida Vaccine Portfolio with Three New Antigens via Series of Rights Acquisitions
GRAND FORKS, ND – June 10, 2014 – NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections, today announced that it has acquired the rights, in four separate transactions, to three well-studied Candida vaccine antigens, significantly bolstering the Company’s Candida vaccine pipeline. These three antigens are in addition to the ...
-
AJ Vaccines expands capacity with a comprehensive reconstruction and renovation of its Polio vaccine production
AJ Vaccines has initiated a total reconstruction and expansion of its existing Polio vaccine production facilities. The new facilities will increase production capacity substantially while simultaneously ensuring compliance with future WHO demands for Polio vaccine production and containment. AJ Vaccines and the company’s owner have decided to initiate a comprehensive and needed upgrade of ...
-
Showcase
POP Biotechnologies Vaccine Technology to Enter Phase III Clinical Studies as part of Eubiologics’ COVID-19 Vaccine Candidate, EuCorVac-19
POP Biotechnologies (POP BIO), a Buffalo, NY based biopharmaceutical startup, announces the approval of the plan for a phase 3 clinical study of EuCorVac-19, a COVID-19 vaccine candidate developed by South Korean partner EuBiologics (KOSDAQ: 206650, CEO, Dr. Baik YoungOk, Mr. Seukkeun Choi) from the Ministry of Food and Drug Safety in South Korea. EuCorVac-19, is a protein-based vaccine ...
-
64% vaccine turnout after 2 days, government expects footfall to rise
NEW DELHI: Around 64% of 3,16,375 planned beneficiaries were vaccinated on the first two days of the immunisation drive against Covid-19 that was rolled out on Saturday, preliminary data from states, subject to further correction, compiled by the Centre till Sunday evening showed. Four states — Tamil Nadu, Punjab, Tripura and Puducherry — recorded low turnout of beneficiaries in the ...
-
Next-generation COVID-19 vaccines – looking beyond spike protein and SARS-CoV-1 variants
The accelerated development of vaccines against COVID-19 and their deployment in mass vaccination programmes has been a major public health achievement. The landscape of vaccine development has undergone rapid change in the global response to the pandemic, with the utilization of novel platforms to create new vaccines at an unprecedented speed. Despite the success of current vaccines in ...
-
Aerogen supports global vaccine equity and neonatal health with UNICEF
UNICEF Ireland welcomes two-year partnership with Galway-based Aerogen UNICEF and Aerogen have announced a two-year partnership in support of UNICEF’s work in the areas of global vaccine equity and the health of newborns. In 2021, Aerogen has committed €50,000 to go towards funding UNICEF’s delivery of 2 billion COVID-19 vaccines to the most vulnerable families, health workers ...
By Aerogen
-
ImmunAdd team wins 18th National Award in the Academic Research
Our team was awarded the 18th National Award in the Academic Research for “the Discovery of IA05 as a Novel Saponin Adjuvant for Therapeutic ...
-
What are the MOST VACCINATED countries in the world?
The UAE leads the way in terms of the percentage of its population which could be covered by the number of vaccines that it has administered. According to the stats provided by Bloomberg’s COVID-19 tracker, the UAE has given 15.6 million doses of a viable vaccine to its citizens, which is sufficient to cover 72.4% of the population. Indeed, other metrics also demonstrate how admirably the ...
-
Micron Biomedical Presents at the White House Summit on the Future of COVID-19 Vaccines
Dr. Mark Prausnitz, co-founder and Chief Scientific Advisor of Micron Biomedical (“Micron”), today presented Micron’s technology for the simple administration of vaccines and therapeutics at a White House panel discussion titled Innovation in Vaccine Delivery chaired by Dr. Francis Collins. This summit outlined a path toward innovative, next-generation COVID-19 vaccines and ...
-
NovaDigm Therapeutics’ Chief Executive Officer, Timothy Cooke, Appointed to the National Vaccine Advisory Committee
GRAND FORKS, N.D.--(BUSINESS WIRE)--NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections, today announced that Timothy Cooke, Ph.D., NovaDigm’s Chief Executive Officer, has been appointed to a four-year term on the National Vaccine Advisory Committee (NVAC) by Karen B. DeSalvo, M.D., MPH, MSc, Acting Assistant Secretary for Health at the U.S. ...
-
Abera’s New Vaccine Platform Validated In Published PHD Thesis
Abera Bioscience AB receives a grant from Vinnova, Sweden’s innovation agency, of SEK 400,000 within the call “Preparatory project for international application in health 2021”. Abera intends to attract the leading experts in the field and build a competitive consortium and project for the development of vaccines based on the company’s platforms to attract funding from the ...
-
BOHS issues interim advisory note on Vaccination in the Workplace
The British Occupational Hygiene Society, a leading scientific charity and the Chartered Society for Worker Health Protection has issued interim advice on vaccination in the workplace. The British Occupational Hygiene Society, a leading scientific charity and the Chartered Society for Worker Health Protection has issued interim advice on vaccination in the workplace. With the ...
-
ICMA and National League of Cities CEOs Encourage Trust in Health & Safety of COVID Vaccine
With the recent approval of a COVID-19 vaccine, there is great hope that there will soon be an end to what is arguably the most painful and deadliest public health crisis in our country’s history. While a mass vaccination program, now underway, will bring healing to a nation that has witnessed more than 300,000 COVID deaths, medical authorities tell us that we are still months away from ...
-
Visit us in MEDICA - 15/18 November
We will soon be able to meet in person at the Medica fair in Düsseldorf. This year we will be in HALL 5 - Stand J26 We are looking forward to meeting with all of you, after so much time of videoconferences and calls The countdown begins. See you very soon #vaccinated #readyforall ...
-
SpyBiotech featured in The Guardian Value of Vaccines supplement
SpyBiotech has today been featured in The Guardian’s Value of Vaccines supplement, discussing the technological solutions we have developed to accelerate vaccine generation for COVID-19 variants and potentially a range of other diseases for which there are no approved treatments. "The COVID-19 vaccine uses SpyBiotech's unique protein "superglue" technology to display the SARS ...
-
Malaria Vaccine Phase 2b Clinical Trial Results Published in Preprints with The Lancet
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the pre-print publication of data from a Phase 2b clinical trial in children demonstrating 77 percent efficacy for a malaria vaccine candidate, R21, created by the University of Oxford that includes Novavax' Matrix-M™ adjuvant and is licensed to Serum ...
By Novavax
-
Abera Receives grant from Vinnova
Abera Bioscience AB receives a grant from Vinnova, Sweden’s innovation agency, of SEK 400,000 within the call “Preparatory project for international application in health 2021”. Abera intends to attract the leading experts in the field and build a competitive consortium and project for the development of vaccines based on the company’s platforms to attract funding from the ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you